@article{3189405,
    title = "Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal
Aortic Aneurysms: a Systematic Review",
    author = "Mohamed, Naser and Galyfos, George and Anastasiadou, Christiana and and Sachmpatzidis, Ioannis and Kikiras, Konstantinos and Papapetrou, and Anastasios and Giannakakis, Sotirios and Kastrisios, Georgios and and Papacharalampous, Gerasimos and Geroulakos, Georgios and Maltezos, and Chrisostomos",
    journal = "Annals of Vascular Surgery",
    year = "2020",
    volume = "63",
    pages = "399-408",
    publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",
    issn = "0890-5096",
    doi = "10.1016/j.avsg.2019.09.016",
    abstract = "Background: This review aims to collect all available data on early and
late outcomes in patients undergoing fenestrated endovascular aortic
aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic
aneurysms (AAAs).
Methods: The Pubmed, Embase, Scopus and Cochrane Library databases were
systematically searched to identify eligible studies. Studies reporting
at least early mortality after F-EVAR in patients with pararenal or
juxtarenal AAA were included. Thirty-day outcomes were defined as early,
and outcomes reported after 30 days postoperatively were defined as
late. Basic characteristics of all studies and demographics of patients
were reported.
Results: Overall, 30 studies (17 retrospective and 13 prospective)
including 23,385 patients in total were included. Out of 23,385
patients, a total of 2,271 patients were treated with F-EVAR for
pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be
treated (data from 24 studies). Pooled early mortality reached 2.55%
(ranging from 0% to 6.74%), with a pooled technical success of 96.8%
(ranging from 82.8% to 100%). Regarding late outcomes, pooled allcause
mortality reached 17% (ranging from 0% to 50%), 1-year primary
patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention
rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up
ranged from 3 to 60 months.
Conclusions: Early outcomes indicate that F-EVAR is a safe and efficient
treatment for patients with pararenal/juxtarenal AAAs. Although
long-term outcomes are acceptable, late-intervention rate remains high."
}